Biểu đồ giá cổ phiếu ALXO
ALXO Dự đoán giá cổ phiếu
ALX Oncology Holdings Inc
$2.08
11.22%
$0.2
Khi đóng cửa: May 08, 16:00:00 GMT-4
$1.97
-5.28%
$-0.11
Phiên sau giờ: May 08, 20:00:00 GMT-4
Quay lại
ALX Oncology Holdings Inc (ALXO) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$1.87
Giá mở cửa
$1.89
Phạm vi ngày
$1.76 - $2.1
Phạm vi 52 tuần
$0.404 - $2.66
Khối lượng
998.6K
Khối lượng trung bình
790.6K
Tỷ suất cổ tức
--
EPS (TTM)
-1.90
Vốn hóa thị trường
$259.2M
ALXO là gì?
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 43 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
